← Back to Clinical Trials
Recruiting NCT06892171

The Study of the Phenotype of Hereditary Xerocytosis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Xerocytosis
Sponsor Centre Hospitalier Universitaire, Amiens
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 10 Years
Max Age N/A
Start Date 2025-03-01
Completion 2028-03
Interventions
Blood sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Hereditary xerocytosis is a dominant red blood cell membrane disorder characterized by an increased leakage of potassium from the interior to the exterior of the red blood cell membrane, leading to water loss, red cell dehydration, and chronic hemolysis. In 90% of cases, it is associated with heterozygous gain-of-function mutations in PIEZO1, a gene that encodes a mechanotransducer responsible for converting mechanical stimuli into biological signals. The remaining 10% of cases are linked to mutations in the GARDOS channel gene.

Eligibility Criteria

Inclusion Criteria: * Any patient diagnosed with hereditary xerocytosis according to the 2021 PNDS guidelines * Covered by a social security plan * Signature of the consent form for study participation by the patient, or for minors, by the parent(s)/legal representative(s). Exclusion Criteria: * patients with other hemolysis reason

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}